ICE3 – Landmark
US Clinical Trial

We are dedicated to providing reliable clinical support for ProSense™, so that physicians and other stakeholders can adopt the technology with confidence as the gold standard in tumor therapy.


ICE3 is the largest controlled multilocation clinical trial ever performed for nitrogen-based cryoablation of small, low-risk, early-stage malignant breast tumors without subsequently removing them. The trial began in 2014 and involves 19 hospitals and medical centers across the US, including Columbia University Medical Center and Mount Sinai Beth Israel.

An initial overview of the ICE3 trial was presented at the Annual Meeting of The American Society of Breast Surgeons.

For further information, please
click here.

The ASBrS has recently published modified guidelines in favor of cryoablation.

Contact us for details